Presentations will showcase the company’s latest advances enabled by its CRISPR by Design TM approach to engineer safer and more effective in vivo genetic medicines for cardiometabolic disease ALAMEDA ...
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results